Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Little Sophia Williams died in a children's hospital in Edinburgh on June 5.
Dry spells over parts of Scotland in the next few days and remain dry. More rain in the north. Temperature will remain mild.
The world's largest aircraft crashed on its second test flight - despite only going 5mph.